LON­DON — Many in­vestors were un­der­whelmed by No­vo’s ar­tic­u­la­tion of its strat­e­gy at the com­pa­ny’s cap­i­tal mar­kets day on Mon­day, and Mike Doust­dar knows it...

The FDA has is­sued a warn­ing let­ter to com­pounder Em­pow­er Phar­ma­cy over its GLP-1 weight loss treat­ments. It’s the third warn­ing the Hous­ton-based com­pa­ny has...

Amer­i­can trade of­fi­cials on Tues­day heard tes­ti­mo­ny for and against an in­ves­ti­ga­tion linked to Ger­many's de­clin­ing pay­ments for drugs, as EU-based phar­ma ex­ec­u­tives are push­ing...

Ver­tex Phar­ma­ceu­ti­cals re­port­edthat an ex­per­i­men­tal kid­ney dis­ease drug called in­axaplin im­proved mea­sures on a urine test in two dif­fer­ent pa­tient pop­u­la­tions, rais­ing op­ti­mism ahead...

Celldex said its ex­per­i­men­tal treat­ment bar­zolvolimab hit its pri­ma­ry end­point in two Phase 3 tri­als, even as the read­out raised safe­ty con­cerns on two life-threat­en­ing...

Viking Ther­a­peu­tics says pa­tients who switched to a once-a-month dos­ing reg­i­men of its obe­si­ty drug did not re­gain much weight af­ter 12 weeks, bol­ster­ing the po­ten­tial...